San Jose, California (PRWEB) January 13, 2014
Follow us on LinkedIn – Stem Cells represent one of the most rapidly growing areas of biotechnology, and investors are currently injecting money into the development of stem cell therapies for a broad range of hard-to-treat diseases. The adult stem cells market is huge compared to cord blood and embryonic stem cell markets. Implementation of various governmental regulations is expected to drive growth in stem cell research over the coming years. The economic and medical potential of stem cell research is encouraging huge investments in the sector by governments, as well as pharmaceutical and biotechnology companies.
The use of human cells as clinical therapies for the treatment of various diseases has undergone a dramatic expansion in the last few years, thus leading to the development of a new branch in medical science – regenerative medicine. Regenerative medicine is a science that involves introduction of cells into the human body with the aim of replacing diseased or dying cells with healthy ones. A plethora of information pertaining to the biology and differentiation potential of Mesenchymal Stem Cells is available, and several thousands of publications have thrown light on the heterogenic nature of the MSC population, depending on species, donor and source tissue characteristics. Thus, MSCs represent one of the most promising systems for cell therapy due to their partial ability to ape embryonic stem cells, and other advantages associated with ethical implications, expandability, availability, and transplantability.
Mesenchymal Stem Cells, mainly found in the bone marrow, are multipotent stem cells that can differentiate into various
Copyright©2012 Vocus, Inc.
All rights reserved